Chinese self-developed kits are constantly making breakthroughs and quickly winning orders from multiple countries
Source: Jinri toutiao
Original: Click here
Top 10 Market Cap Chinese Medical Device Companies: Champions and Runners-Up
► Top 10 Chinese medical device companies are selected by market capital.
► Mindray Medical has the highest market cap but is too big to keep R&D-driven.
The Chinese A-share market is experiencing a boom, with a record deal value amount at over CNY 1.5 trillion within four trading days. This craze surely has a powerful impact on the medical devices field – a fast-growing business.
The medical device industry in China sped up only in recent years due to substantial capital injections, advanced technologies and supportive policies. The current premature stage indicates much potential for growth soon and the exciting emergence of new high-tech companies.
A glance at top 10 Chinese medical devices by market cap
Here, the top 10 Chinese medical device companies are mentioned, to provide a brief look into local benchmarks in the industry. Some companies have been steadily operating for over 20 years and are recently moving into a new growth stage or reorienting in unprecedented directions due to fierce market competition. Some younger companies have quickly found their value position by advanced resource-upgrading throughout the industry chain.
Among the ten companies, there are two clinical medical equipment companies, three high-value medical device providers (such as heart stents, orthopedics implants and ophthalmology), four IVD manufacturers and only one in the home-use medical device area.
Based on a general overview of the top ten companies, some companies stand out from the rest. Besides Mindray (300760:SZ), which has the highest market cap, Yuyue Medical (002223:SZ) at 10th position is the only listed home-use medical device company in the top-ten market cap rank.
Mindray: too big to sprint
Mindray, the champion company, stands at the top position with an unbeatable valuation of over CNY 380 billion. As suggested by EqualOcean’s fundamental analysis, the company has come this far through frequent acquisitions and strengthening regional distribution channels. The conglomerate provides equipment in life information and support, IVD (in vitro diagnosis) and medical imaging. These three major businesses have been hot picks since the outbreak of COVID-19.
However, the conglomerate relies more on the robust R&D foundation and strong global selling network. When a company gets bigger, the slower the giant grows – an aspect especially indicated by the R&D efficiency.
Yuyue: keeping agile in the C-end selling
Even though Yuyue medical is ranked 10th in the top ten list, it is the champion company in the home-use medical device segment. One advantage for companies in this segment is that they have more flexibility in selling strategies because they provide end consumers with small medical gadgets, from sphygmomanometers to glucose meters, massage devices, etc.
As a previous EqualOcean analysis said, they can not only invest in developing their technology (R & D) but also seek a new growth direction as they shift to a more efficient selling strategy. This is exactly what Yuyue has been trying and will continue to try in the near future.
The COVID-19 crisis has created a mania for home healthcare. Yuyue has spared no effort in utilizing this trend. It has been cooperating with the two most prominent e-commerce platforms in China, Taobao and JD.com. Now the online vendor has an over 1.13 million followers on the Taobao platform alone, with an over 480 thousand sales record of one single SKU (Stock Keeping Unit) – a household digital manometer.
BGI Genomics Plans to Raise CNY 2 billion to Expand Diagnosis Project
Nucleic Acid Testing Accelerates, BGI Genomics Shares up 92.95% This Year
BGI Genomics Benefits from Overseas Epidemic, Buying Financial Services with Cash While Raising CNY 500 million in debt
BGI Genomics's BRCA1/2 Gene Mutation Detection Kit Passes Approval for Innovative Medical Devices by SFDA
Chinese Genomics MGI Tech Gets USD 1 Billion in Biotech PE Bullpen
MGI Tech (华大智造), a Shenzhen-based gene sequencing equipment supplier, has completed its Series B financing round, worth USD 1 billion, led by a series of venture capitalists and private equity heavyweights. The firm had previously raised over USD 200 million from Goldstone, Orient Securities and Green Pine Capital Partners in 2019.
The firm was founded as the subsidiary of BGI Group, the parent company of the Chinese genomics heavyweight BGI Genomics (华大基因) (300676:SH). The BGI Group subsidiary has been primarily been producing clinical gene sequencers but has also been providing genetic sequencing, medical imaging, and laboratory automation products and services.
Both MGI Tech and BGI Genomics are strategic companies in China's life sciences and healthcare scene. The sister companies are regarded as the country's first globally-competitive set of genome sequencing companies.
Check this in-depth article on how BGI Genomics helped Chinese companies to resume work after Covid-19.
Chinese genomics pioneers have used foreign acquisitions in their quest to become competitive in the field, as well. In March 2013, Complete Genomics was acquired by BGI Genomics. In 2018, Complete Genomics became part of MGI, which was the instrument manufacturing business of BGI.
Since the beginning of the pandemic, BGI Genomics has initiated a plethora of new businesses and expanded its operational network across geographies. It even received a formal Emergency Use Authorization from the US Food and Drug Administration in March 2020.
BGI Genomics' stock price jumped around 100% from CNY 66 levels to CNY 124 between January 1st and May 28 of 2020. Meanwhile, its total revenues reached around USD 394 million in 2019 with approximately 17.8% CAGR from 2012 to 2019. Healthcare, biotech and IT industry-related deals outperformed in private equity markets in the first quarter of 2020 due to the COVID-19 related paradigm shifts.
MGI Tech did not immediately answer EqualOcean's inquiry about this financing round.
BGI Genomics to Repurchase Shares with CNY 300 to 600 million
BGI Genomics saw its stock price fell 3.3% to CNY 101.44 dramatically.
Announcement of BGI Genomics on the change of medical device registration certificate of the wholly-owned subsidiary.
BGI Genomics disclosed ESOP
EqualOcean is an international information service provider and investment research firm that aims to become a global platform for industrial innovation.
We strive to make technology inclusive, accessible and transparent.
Join over 70,000 of your peers
9 Xiaguangli, 10F Block A CEC Development Mansion, Chaoyang Dc, Beijing 100125, China
A002, 5F, Ai Tower, 701 Yunjin Road, Xuhui Dc, Shanghai 200232, China
800 Third Ave, 28F, New York, NY 10022, USA
Interviews with analysts
Products & prices
Customers & evaluation
Copyright ©2020 EqualOcean.com. All rights reserved.